STING1 and neoplasm: In summary, we developed a multifunctional nanoassembly (MD1a NP) by co-assembling a HOCl-responsive dimer prodrug, MB–DOX, with a STING agonist, 1a, to elicit personalized antitumor immunity and overcome tumor immunosuppression.